Our Blog | Biosimilars & Generics | AAM

GRx+Biosims - No-cost FDA workshop limited to first 100 who sign up. Act now!

Oct 3, 2019 | Jennifer Soup

GRx+Biosims Spotlight: The Exposition

Sep 26, 2019 | Craig Burton

Three Recommendations to Save Money for Seniors and Taxpayers by Updating Medicare Part D

Sep 23, 2019 | Erica Klinger

Happy Birthday, Generic Prescription Drugs: 35 Years of Competition

Aug 26, 2019 | Erica Klinger

Giving, Volunteering and More: How Our Members Show They Care

Jul 30, 2019 | Ashlie Van Meter

A Generic Summer Savings Tour: How Did Your State Do?

Jul 29, 2019 | Maddy Murphy

Prescription Drug Safety on Campus

Jul 11, 2019 | Jonathan Kimball

The House Has Spoken – It’s Time to Fix USMCA’s Pharmaceutical Provisions

Jun 26, 2019 | Jennifer Soup

GRx+Biosims 2019: Register Now and Be Part of the Solution

Jun 25, 2019 | Erik Komendant

Section 205 is Still Flawed and Erodes the Only Incentive to Challenge Brand-Name Drug Patents. Here’s Why.

Jun 19, 2019 | Chip Davis

Congress: Don’t Punish American Patients

May 29, 2019 | Erica Klinger

Five Lessons from a National Collaboration to Promote Prescription Drug Safety

May 28, 2019 | Jewel Smith

Join AAM Today!